Postbiotic innovation   Hero C30 image

Postbiotic innovation at ADM

ADM is driving postbiotic innovation on a global scale. Backed by our advanced proprietary microbiome research capabilities, we deliver science-led postbiotic solutions specifically targeted to meet evolving consumer needs.   

Postbiotic innovation   Hero C30 image
Postbiotic innovation   Pre clinical discovery C12 image

From preclinical discovery to commercial scale

ADM’s cutting-edge postbiotic innovations are grounded in preclinical discovery and industry-leading microbiome research—and are shaped by the need for better solutions for consumers, manufacturers, researchers, and professionals alike.


Every ingredient we formulate is subjected to rigorous in vitro, preclinical, and human studies, and today our clinical evidence base is among the deepest in the industry. You also get more than a science-backed ingredient. With ADM, you’ll get a partner from concept to full-scale commercial production.


ADM’s industry experts and global capabilities enable us to provide end-to-end support, from formulation support to application development to finished-format manufacturing at our state-of-the-art production facility. Together, we’ll help you to get to market faster with premium solutions that connect with consumers. 

Advancing postbiotics— the ADM way

From identifying a solution to validating it in rigorous scientific studies to developing the finished product, ADM’s postbiotic solutions are backed by advanced clinical capabilities, industry experts, and an expansive global network. 

Postbiotic innovation   How ADM Advances C37 image

Discover

Combining our proprietary microbiome research and advanced capabilities, from DNA sequencing to C. elegans testing models, we identify highly targeted microbiome solutions.

Validate

Our range of cutting-edge postbiotic solutions is validated by rigorous preclinical and clinical human trials, with 14 clinical studies published so far, plus more to come.

Formulate

Our postbiotics are heat-treated and non-living, making them highly stable and much easier to formulate across a wide range of formats for foods, beverages, supplements, and more.

Manufacture

ADM offers a cutting-edge dedicated production facility for postbiotics, delivering finished-format manufacturing, a vertically integrated supply chain, and global logistics capability.

Postbiotic innovation   Capabilities from lab to launch Discover C56 image
Discover and validate with science

Our proprietary microbiome research begins with extensive preclinical research on target strains. The best candidates are tested in randomized, double-blind, placebo-controlled human studies to provide scientific evidence of effectiveness.

Postbiotic innovation   Capabilities from lab to launch Formulate C56 image
Formulate for real products

We turn postbiotics into real products people want to use. Our proprietary heat-treated whole-cell technology locks in efficacy while increasing stability, opening up a broad range of formulation possibilities, applications, and delivery formats.

Postbiotic innovation   Capabilities from lab to launch Manufacture C56 image
Manufacture with consistency

ADM’s postbiotics are heat-stable, so they can withstand harsh processing conditions while eliminating the need for dedicated cold manufacturing or cold chain. Finished products are premium-quality and remain effective throughout their shelf-life.

Postbiotic innovation   From BPL1® research C13 image

From strain identification to postbiotic innovation

Postbiotic innovation is unlocking new possibilities. For example, BPL1® Postbiotic (Bifidobacterium animalis subsp. lactis CECT 8145) is developed from our proprietary probiotic strain. Emerging and in vitro evidence suggest it may help support visceral fat reduction in combination with diet and exercise, while offering high formulation flexibility.

Our clinically backed postbiotics

ADM’s industry-leading microbiome research has led to the innovation of three clinically backed, targeted postbiotic products.

Postbiotic detail L. gasseri   Explore more BPL1 C23 image

BPL1® for metabolic health

ADM’s innovative BPL1® Postbiotic is clinically studied to support metabolic health in combination with diet and exercise¹.

Postbiotic detail L. gasseri   Explore more Estflorin1 C23 image

Esflorin1® for digestive health

Clinical evidence shows Esflorin1® Postbiotic may help reduce bloating, and support overall gut health³.   

Postbiotic innovation   Our clinically backed products L. gasseri C23 image

L. gasseri CP2305 for mental wellbeing

With 10 human clinical trials, this is shown to help support stress, mood, sleep, women’s health, and men’s exercise recovery.

Partner with ADM today

We’re shaping the next generation of microbiome solutions. Discover how we can help you, from postbiotic research to new formulations to product development.

Postbiotics portfolio hub   Develop with postbiotics C32 image

This content is intended for business-to-business (B2B) informational purposes only and not directed to consumers. The information provided summarizes scientific research and should not be interpreted as evidence that any ingredient, product, claim, or statement has been approved, authorized, validated, or accepted by any regulatory authority in any jurisdiction. References to scientific studies do not establish that any claim is permitted for use in a particular jurisdiction or product category. The ingredients described in this content are not intended to diagnose, treat, cure, or prevent any disease. Ingredients, permitted uses, and claims must be reviewed under applicable local laws and regulations before use in any specific product, category, or market by companies for their finished products.


Sources


BPL1® and Esflorin1® are trademarks registered for Biopolis S.L. in the EU and other countries. 


¹Pedret et al. (2019), International Journal of Obesity, 43:1863–1868 


²Salminen et al. (2021), Nature Reviews Gastroenterology & Hepatology, 18:649–667 


³Esflorin1® Postbiotic clinical studies: 

Srivastava et al. (2024), Gut Microbes, 16:2338322 

Naghibi et al. (2024), Nutrients, 16:3952 

Cardoso et al. (2026), Allergy, 1–13 


⁴L. gasseri CP2305 Postbiotic clinical studies:  


Sugawara et al. (2016), Microbial Ecology in Health and Disease, 27:30259

Nishida et al. (2017), Journal of Applied Microbiology, 123:1561–1570

Nishida et al. (2017), Journal of Functional Foods, 36:112–121

Nishida et al. (2019), Nutrients, 11:1859

Chu et al. (2023), Clinical Nutrition, 42:1314–1321

Nishida et al. (2021), Journal of Functional Foods, 80:104426

Sawada et al. (2022), Nutrients, 14:1695

Sawada et al. (2019), Journal of Functional Foods, 57:465–476

Tanihiro et al. (2026), Frontiers in Nutrition, 13:1796729

Fuchida et al. (2026), Toxicology Reports, 16:102222